Corrigendum to “Assessment of toxicity and biodistribution of recombinant AAV8 vector–mediated immunomodulatory gene therapy in mice with Pompe disease” (Molecular Therapy - Methods and Clinical Development (2014) 1 (S2329050116300833) (10.1038/mtm.2014.18));Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14018-

  Wang, Gensheng ^a   Young, Sarah P ^b   Bali, Deeksha ^b   Hutt, Julie ^a   Li, Songtao ^b   Benson, Janet ^a   Koeberl, Dwight D ^b  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84921528269     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.2     Document Type: Erratum

References (22)

1. Sun, B, Kulis, MD, Young, S P, Hobeika, AC, Li, S, Bird, A et al. (2010). Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther 18: 353-360.
2. Raben, N, Danon, M, Gilbert, AL, Dwivedi, S, Collins, B, Thurberg, BL et al. (2003). Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80: 159-169.
3. Sun, B, Bird, A, Young, S P, Kishnani, PS, Chen, YT and Koeberl, DD (2007). Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 81: 1042-1049.
4. Kishnani, PS, Corzo, D, Nicolino, M, Byrne, B, Mandel, H, Hwu, WL et al. (2007). Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68: 99-109.
5. van der Ploeg, AT, Clemens, PR, Corzo, D, Escolar, DM, Florence, J, Groeneveld, GJ et al. (2010). A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362: 1396-1406.
6. Sun, B, Zhang, H, Benjamin, DK Jr, Brown, T, Bird, A, Young, SP et al. (2006). Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. Mol Ther 14: 822-830.
7. Zhang, P, Luo, X, Bird, A, Li, S and Koeberl, DD (2012). Deficiency in MyD88 Signaling Results in Decreased Antibody Responses to an Adeno-Associated Virus Vector in Murine Pompe Disease. Biores Open Access 1: 109-114.
8. Kishnani, PS, Nicolino, M, Voit, T, Rogers, RC, Tsai, AC, Waterson, J et al. (2006). Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149: 89-97.
9. Davidoff, AM, Ng, CY, Zhou, J, Spence, Y and Nathwani, AC (2003). Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102: 480-488.
10. Mochizuki, S, Mizukami, H, Ogura, T, Kure, S, Ichinohe, A, Kojima, K et al. (2004). Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther 11: 1081-1086.
11. Chulay, JD, Ye, GJ, Thomas, DL, Knop, DR, Benson, JM, Hutt, JA et al. (2011). Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum Gene Ther 22: 155-165.
12. Koeberl, DD and Kishnani, PS (2009). Immunomodulatory gene therapy in lysosomal storage disorders. Curr Gene Ther 9: 503-510.
13. Zhang, P, Sun, B, Osada, T, Rodriguiz, R, Yang, XY, Luo, X et al. (2012). Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum Gene Ther 23: 460-472.
14. Cao, O, Dobrzynski, E, Wang, L, Nayak, S, Mingle, B, Terhorst, C et al. (2007). Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110: 1132-1140.
15. Ziegler, RJ, Cherry, M, Barbon, CM, Li, C, Bercury, SD, Armentano, D et al. (2007). Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. Mol Ther 15: 492-500.
16. Franco, LM, Sun, B, Yang, X, Bird, A, Zhang, H, Schneider, A et al. (2005). Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 12: 876-884.
17. Messinger, YH, Mendelsohn, NJ, Rhead, W, Dimmock, D, Hershkovitz, E, Champion, M et al. (2012). Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 14: 135-142.
18. Ill, CR, Yang, CQ, Bidlingmaier, SM, Gonzales, JN, Burns, DS, Bartholomew, RM et al. (1997). Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A. Blood Coagul Fibrinolysis 8 (suppl. 2): S23-S30.
19. Wang, L, Takabe, K, Bidlingmaier, SM, Ill, CR and Verma, IM (1999). Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 96: 3906-3910.
20. Amalfitano, A, McVie-Wylie, AJ, Hu, H, Dawson, TL, Raben, N, Plotz, P et al. (1999). Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci USA 96: 8861-8866.
21. Kikuchi, T, Yang, HW, Pennybacker, M, Ichihara, N, Mizutani, M, Van Hove, JL et al. (1998). Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 101: 827-833.
22. An, Y, Young, S P, Hillman, SL, Van Hove, JL, Chen, YT and Millington, DS (2000). Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. Anal Biochem 287: 136-143.